首页> 外文期刊>Therapeutics and Clinical Risk Management >Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database
【24h】

Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database

机译:他汀类药物对新发糖尿病风险的影响:一项使用韩国国民健康保险理赔数据库的基于人群的队列研究

获取原文
           

摘要

Statin therapy is beneficial in reducing cardiovascular events and mortalities in patients with atherosclerotic cardiovascular diseases. Yet, there have been concerns of increased risk of diabetes with statin use. This study was aimed to evaluate the association between statins and new onset diabetes mellitus (NODM) in patients with ischemic heart disease (IHD) utilizing the Korean Health Insurance Review and Assessment Service claims database. Among adult?patients with preexisting IHD, new statin users and matched nonstatin users were identified on a 1:1 ratio using proportionate stratified random sampling by sex and age. They were subsequently propensity score matched further with age and comorbidities to reduce the selection bias. Overall incidence rates, cumulative rates and hazard ratios (HRs) between statin use and occurrence of NODM were estimated. The subgroup analyses were performed according to sex, age groups, and the individual agents and intensities of statins. A total of 156,360 patients (94,370 in the statin users and 61,990 in the nonstatin users) were included in the analysis. The incidence rates of NODM were 7.8% and 4.8% in the statin users and nonstatin users, respectively. The risk of NODM was higher among statin users (crude HR 2.01, 95% confidence interval [CI] 1.93–2.10; adjusted HR 1.84, 95% CI 1.63–2.09). Pravastatin had the lowest risk (adjusted HR 1.54, 95% CI 1.32–1.81) while those who were exposed to more than one statin were at the highest risk of NODM (adjusted HR 2.17, 95% CI 1.93–2.37). It has been concluded that all statins are associated with the risk of NODM in patients with IHD, and it is believed that our study would contribute to a better understanding of statin and NODM association by analyzing statin use in the real-world setting. Periodic screening and monitoring for diabetes are warranted during prolonged statin therapy in patients with IHD.
机译:他汀类药物疗法有助于减少动脉粥样硬化性心血管疾病患者的心血管事件和死亡率。然而,有人担心使用他汀类药物会增加患糖尿病的风险。这项研究旨在利用韩国健康保险审查与评估服务索赔数据库评估他汀类药物与缺血性心脏病(IHD)患者新发糖尿病(NODM)之间的关联。在已有IHD的成年患者中,按性别和年龄按比例分层抽样,以1:1的比例确定了新的他汀类药物使用者和相配的非他汀类药物使用者。随后将他们的倾向得分与年龄和合并症进一步匹配,以减少选择偏见。估计他汀类药物使用与NODM发生之间的总发生率,累积率和危险比(HRs)。根据性别,年龄组以及他汀类药物的个体作用和强度进行亚组分析。分析总共包括156,360名患者(他汀类药物使用者94,370例,非他汀类药物使用者61,990例)。他汀类药物使用者和非他汀类药物使用者的NODM发生率分别为7.8%和4.8%。他汀类药物使用者的NODM风险较高(粗HR 2.01,95%置信区间[CI] 1.93–2.10;校正后HR 1.84,95%CI 1.63–2.09)。普伐他汀的风险最低(HR调整为1.54,95%CI 1.32–1.81),而暴露于一种以上他汀类药物的人NODM风险最高(HR调整为2.17,95%CI 1.93–2.37)。已经得出的结论是,所有他汀类药物均与IHD患者的NODM风险有关,并且相信我们的研究将通过分析现实环境中他汀类药物的使用,有助于更好地了解他汀类药物与NODM的关联。在IHD患者长期接受他汀类药物治疗期间,应定期进行糖尿病筛查和监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号